Weight gain recommendations US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Weight gain recommendations. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Weight gain recommendations US Medical PG Question 1: You have been entrusted with the task of finding the causes of low birth weight in infants born in the health jurisdiction for which you are responsible. In 2017, there were 1,500 live births and, upon further inspection of the birth certificates, 108 of these children had a low birth weight (i.e. lower than 2,500 g), while 237 had mothers who smoked continuously during pregnancy. Further calculations have shown that the risk of low birth weight in smokers was 14% and in non-smokers, it was 7%, while the relative risk of low birth weight linked to cigarette smoking during pregnancy was 2%. In other words, women who smoked during pregnancy were twice as likely as those who did not smoke to deliver a low-weight infant. Using this data, you are also asked to calculate how much of the excess risk for low birth weight, in percentage terms, can be attributed to smoking. What is the attributable risk percentage for smoking leading to low birth weight?
- A. 40%
- B. 30%
- C. 20%
- D. 10%
- E. 50% (Correct Answer)
Weight gain recommendations Explanation: ***50%***
- This value is calculated using the formula for **attributable risk percent (ARP)** in the exposed group: ARP = ((Risk in exposed - Risk in unexposed) / Risk in exposed) × 100.
- Given that the risk of low birth weight in smokers (exposed) is 14% and in non-smokers (unexposed) is 7%, the calculation is ((0.14 - 0.07) / 0.14) × 100 = (0.07 / 0.14) × 100 = **0.50 × 100 = 50%**.
*40%*
- This percentage does not align with the provided risk values for low birth weight in smokers (14%) and non-smokers (7%).
- A calculation of ((0.14 - 0.07) / 0.14) * 100 does not yield 40%.
*30%*
- This value is incorrect, as it would suggest a smaller difference in risk between the exposed and unexposed groups relative to the risk in the exposed group than what is presented in the problem.
- The calculated attributable risk percent is higher than 30%.
*20%*
- This option is significantly lower than the true attributable risk percent derived from the given risk figures.
- It would imply a much weaker association between smoking and low birth weight in terms of excess risk than what is calculated.
*10%*
- This value is substantially different from the correct calculation and would suggest a very minor attributable risk.
- The attributable risk percent for smoking leading to low birth weight is much higher than 10% based on the provided data.
Weight gain recommendations US Medical PG Question 2: A 24-year-old primigravida presents to her physician for regular prenatal care at 31 weeks gestation. She has no complaints and the antepartum course has been uncomplicated. Her pre-gestational history is significant for obesity (BMI = 30.5 kg/m2). She has gained a total of 10 kg (22.4 lb) during pregnancy, and 2 kg (4.48 lb) since her last visit 4 weeks ago. Her vital signs are as follows: blood pressure, 145/90 mm Hg; heart rate, 87/min; respiratory rate, 14/min; and temperature, 36.7℃ (98℉). The fetal heart rate is 153/min. The physical examination shows no edema and is only significant for a 2/6 systolic murmur best heard at the apex of the heart. A 24-hour urine is negative for protein. Which of the following options describe the best management strategy in this case?
- A. Treatment in outpatient settings with labetalol
- B. Treatment in the outpatient settings with nifedipine
- C. Observation in the outpatient settings (Correct Answer)
- D. Treatment in the inpatient settings with methyldopa
- E. Admission to hospital for observation
Weight gain recommendations Explanation: ***Observation in the outpatient settings***
- The patient's blood pressure is 145/90 mmHg, which meets the criteria for **gestational hypertension** according to ACOG (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg on two occasions at least 4 hours apart after 20 weeks gestation in a previously normotensive woman, without proteinuria).
- Since this is a single elevated blood pressure reading (not yet confirmed by a second reading after 4 hours) and there is no evidence of **proteinuria** or **severe features** (e.g., severe headache, visual disturbances, epigastric pain, elevated liver enzymes, thrombocytopenia, pulmonary edema), **close outpatient monitoring** is the appropriate initial step.
*Treatment in outpatient settings with labetalol*
- **Antihypertensive medication** is typically initiated for gestational hypertension if BP is consistently ≥160/110 mmHg, or if there are signs of severe features.
- While labetalol is a safe and common first-line agent, starting treatment based on a **single, non-severe elevated BP reading** without confirmed gestational hypertension or severe features is premature.
*Treatment in the outpatient settings with nifedipine*
- Similar to labetalol, **nifedipine** is an appropriate antihypertensive if medication is warranted for gestational hypertension.
- However, initiating medication is not the **first step** for an isolated, non-severe elevated blood pressure reading without confirmed diagnosis or severe features.
*Treatment in the inpatient settings with methyldopa*
- **Inpatient treatment** is reserved for patients with severe gestational hypertension, preeclampsia with severe features, or uncontrollable hypertension.
- While methyldopa is a safe antihypertensive in pregnancy, inpatient treatment is **not indicated** for this patient's presentation.
*Admission to hospital for observation*
- **Hospital admission** for observation is generally reserved for patients with more severe hypertension, suspected preeclampsia with severe features, or concerns about fetal well-being.
- Given the patient's **asymptomatic state**, normal fetal heart rate, and lack of proteinuria or severe features, inpatient admission is **unnecessary** at this stage.
Weight gain recommendations US Medical PG Question 3: A 21-year-old primigravid woman comes to the physician at 10 weeks' gestation because of progressive fatigue for the past 3 weeks. She reports that she has had a 3.2-kg (7-lb) weight loss after conceiving despite an increase in appetite. She has become increasingly anxious and has trouble falling asleep. There is no personal or family history of serious illness. Medications include folic acid and a multivitamin. She is 165 cm (5 ft 5 in) tall and weighs 55 kg (120 lb); BMI is 20 kg/m2. Her temperature is 37.4°C (99.4°F), pulse is 120/min, respirations are 18/min, and blood pressure is 150/70 mm Hg. The globes of the eyes are prominent. The thyroid gland is firm and diffusely enlarged. Neurologic examination shows a fine resting tremor of the hands. There is a midsystolic click at the apex and a grade 2/6 early systolic murmur at the upper left sternal border. Serum thyroid-stimulating hormone concentration is 0.1 μU/mL. An ECG is normal except for sinus tachycardia. Which of the following is the most appropriate next step in management?
- A. Radioactive iodine ablation
- B. Lugol's iodine
- C. Atenolol
- D. Propylthiouracil (Correct Answer)
- E. Thyroidectomy
Weight gain recommendations Explanation: ***Propylthiouracil***
- The patient presents with classic symptoms of **hyperthyroidism** (**fatigue, weight loss despite increased appetite, anxiety, tachycardia, prominent globes, fine tremor, diffusely enlarged thyroid**, and a **TSH of 0.1 μU/mL**), likely **Graves' disease** given her age and presentation.
- **Propylthiouracil (PTU)** is the preferred antithyroid drug during the **first trimester of pregnancy** due to a lower risk of teratogenicity compared to methimazole, especially preventing **embryopathy** (aplasia cutis).
*Radioactive iodine ablation*
- **Radioactive iodine (RAI) ablation** is **contraindicated in pregnancy** as it crosses the placenta and can cause **fetal hypothyroidism** and **cretinism** by destroying the fetal thyroid gland.
- It is typically used for definitive treatment of hyperthyroidism in non-pregnant individuals or post-pregnancy.
*Lugol's iodine*
- **Lugol's iodine (potassium iodide)** is used in the short term to acutely block thyroid hormone release, primarily as preparation for thyroidectomy or in **thyroid storm**.
- It is not a primary long-term treatment for hyperthyroidism and can be problematic in pregnancy due to potential for fetal goiter and hypothyroidism with prolonged use.
*Atenolol*
- **Atenolol**, a **beta-blocker**, can relieve adrenergic symptoms of hyperthyroidism like tachycardia, tremors, and anxiety.
- However, it does not address the underlying **excessive thyroid hormone production** and has been associated with **fetal growth restriction** and **bradycardia** in pregnancy. **Propranolol** is a safer beta-blocker if needed during pregnancy but should be used cautiously.
*Thyroidectomy*
- **Thyroidectomy** is a definitive treatment for hyperthyroidism but is usually reserved for patients who fail medical therapy or have large goiters causing compressive symptoms, and its preferred timing is during the **second trimester of pregnancy** if indicated, to minimize risks to both mother and fetus.
- It is not the most appropriate initial management step for an uncomplicated presentation of hyperthyroidism in early pregnancy.
Weight gain recommendations US Medical PG Question 4: A 65-year-old man presents to the diabetes clinic for a check-up. He has been successfully managing his diabetes through diet alone, and has not experienced any complications related to retinopathy, neuropathy, or nephropathy. He recently started a new exercise regimen and is eager to see whether his weight has declined since his last visit. The nurse measures his height to be 170 cm and his weight to be 165 lb (75 kg). What range does this patient’s body mass index currently fall into?
- A. < 18.5
- B. > 30.0
- C. 25.0 - 29.9 (Correct Answer)
- D. 18.5 - 24.9
- E. > 40.0
Weight gain recommendations Explanation: ***25.0 - 29.9***
- To calculate BMI, divide weight in kilograms by the square of height in meters: Weight = 75 kg, Height = 1.70 m.
- BMI = 75 / (1.70 * 1.70) = 75 / 2.89 ≈ **25.95 kg/m²**, which falls within the **overweight** range of 25.0 to 29.9.
*< 18.5*
- A BMI less than 18.5 indicates **underweight**.
- The calculated BMI of approximately 25.95 is significantly higher than this range.
*> 30.0*
- A BMI greater than 30.0 indicates **obesity**.
- The calculated BMI of approximately 25.95 is below this threshold, indicating the patient is not obese.
*18.5 - 24.9*
- A BMI between 18.5 and 24.9 is considered the **normal or healthy weight** range.
- The patient's BMI of approximately 25.95 is slightly above this range, placing him in the overweight category.
*> 40.0*
- A BMI greater than 40.0 indicates **morbid obesity** or **Class III obesity**.
- The patient's calculated BMI of 25.95 is substantially lower than this severe obesity classification.
Weight gain recommendations US Medical PG Question 5: A 38-year-old woman, gravida 4, para 3, at 20 weeks' gestation comes to the physician for a prenatal care visit. She used fertility enhancing treatment for her current pregnancy. Her other children were born before 37 weeks' gestation. She is 170 cm (5 ft 7 in) tall and weighs 82 kg (180 lb); BMI is 28.4 kg/m2. Her vital signs are within normal limits. The abdomen is nontender, and no contractions are felt. Ultrasonography shows a cervical length of 22 mm and a fetal heart rate of 140/min. Which of the following is the most likely diagnosis?
- A. Placental insufficiency
- B. Bicornuate uterus
- C. Diethylstilbestrol exposure
- D. Cephalopelvic disproportion
- E. Cervical insufficiency (Correct Answer)
Weight gain recommendations Explanation: ***Cervical insufficiency***
- A **short cervical length** (22 mm at 20 weeks) in a woman with a history of **multiple preterm births (G4P3 before 37 weeks)** is highly indicative of cervical insufficiency, where the cervix prematurely shortens and dilates.
- **Fertility-enhancing treatments** are an additional risk factor, as they often involve manipulations that can weaken the cervix or lead to multiple gestations, further stressing the cervix.
*Placental insufficiency*
- This condition is characterized by **fetal growth restriction** or **fetal distress** due to inadequate nutrient and oxygen supply from the placenta.
- The presented information primarily points to cervical changes, not direct evidence of placental dysfunction affecting fetal growth or well-being (e.g., normal fetal heart rate, no mention of FGR).
*Bicornuate uterus*
- A **bicornuate uterus** is a congenital uterine anomaly that can increase the risk of preterm birth due to a smaller uterine cavity or abnormal uterine contractions.
- However, while it can cause preterm labor, the primary finding here is a very short cervix, suggesting a cervical rather than uterine structural issue as the immediate diagnosis.
*Diethylstilbestrol exposure*
- **Diethylstilbestrol (DES) exposure** *in utero* can lead to reproductive tract abnormalities, including an increased risk of cervical incompetence and preterm birth.
- This diagnosis would require a history of maternal DES exposure during her own *in utero* development, which is not mentioned in the patient's history.
*Cephalopelvic disproportion*
- **Cephalopelvic disproportion (CPD)** is a mismatch between the size of the fetal head and the maternal pelvis, making vaginal delivery difficult or impossible.
- This condition is typically diagnosed later in pregnancy or during labor and is not related to cervical shortening at 20 weeks' gestation or a history of preterm births.
Weight gain recommendations US Medical PG Question 6: A 21-year-old female presents to her primary care doctor for prenatal counseling before attempting to become pregnant for the first time. She is an avid runner, and the physician notes her BMI of 17.5. The patient complains of chronic fatigue, which she attributes to her busy lifestyle. The physician orders a complete blood count that reveals a Hgb 10.2 g/dL (normal 12.1 to 15.1 g/dL) with an MCV 102 µm^3 (normal 78 to 98 µm^3). A serum measurement of a catabolic derivative of methionine returns elevated. Which of the following complications is the patient at most risk for if she becomes pregnant?
- A. Placenta abruptio (Correct Answer)
- B. Placenta previa
- C. Placenta accreta
- D. Neural tube defects
- E. Gestational diabetes
Weight gain recommendations Explanation: **Placenta abruptio**
* The patient presents with several risk factors for **placental abruption**, including **low BMI**, **anemia** (Hgb 10.2), and **elevated homocysteine** (indicated by elevated catabolic derivative of methionine, implying **folate or B12 deficiency**, which leads to high homocysteine).
* **Anemia** and **folate deficiency** are associated with an increased risk of placental abruption.
*Placenta previa*
* **Placenta previa** is characterized by the placenta covering the cervical os, typically associated with risk factors like **previous C-section**, **multiparity**, and **advanced maternal age**.
* The patient's profile (first pregnancy, young) does not align with the typical risk factors for placenta previa.
*Placenta accreta*
* **Placenta accreta** involves abnormal placental adherence to the uterine wall, most commonly linked to **prior uterine surgery** (especially C-sections) and **placenta previa**.
* The patient has no history of uterine surgery, making placenta accreta an unlikely primary risk.
*Neural tube defects*
* **Neural tube defects** are associated with **folate deficiency**, which is likely present given the **macrocytic anemia** (MCV 102) and elevated homocysteine.
* However, the question asks for the complication the patient is *most* at risk for due to her overall profile including her low BMI and anemia, and while NTDs are a risk, the combination of factors points more strongly to placental abruption.
*Gestational diabetes*
* **Gestational diabetes** is linked to risk factors like **obesity**, **family history of diabetes**, and **advanced maternal age**.
* The patient's **low BMI** (17.5) and young age make gestational diabetes an unlikely significant risk.
Weight gain recommendations US Medical PG Question 7: A 37-year-old woman comes to the physician because of irregular menses and generalized fatigue for the past 4 months. Menses previously occurred at regular 25- to 29-day intervals and lasted for 5 days but now occur at 45- to 60-day intervals. She has no history of serious illness and takes no medications. She is 155 cm (5 ft 1 in) tall and weighs 89 kg (196 lb); BMI is 37 kg/m2. Her temperature is 37°C (98.6°F), pulse is 90/min, and blood pressure is 146/100 mm Hg. Examination shows facial hair as well as comedones on the face and back. There are multiple ecchymotic patches on the trunk. Neurological examination shows weakness of the iliopsoas and biceps muscles bilaterally. Laboratory studies show:
Hemoglobin 13.1 g/dL
Leukocyte count 13,500/mm3
Platelet count 510,000/mm3
Serum
Na+ 145 mEq/L
K+ 3.3 mEq/L
Cl- 100 mEq/L
Glucose 188 mg/dL
Which of the following is the most likely diagnosis?
- A. Pheochromocytoma
- B. Cushing syndrome (Correct Answer)
- C. Primary hyperaldosteronism
- D. Polycystic ovarian syndrome
- E. Hypothyroidism
Weight gain recommendations Explanation: ***Cushing syndrome***
- The constellation of **obesity**, **hypertension**, **irregular menses**, **hirsutism** (facial hair), **acne** (comedones), **easy bruising** (ecchymotic patches), **proximal muscle weakness** (iliopsoas and biceps), **leukocytosis**, **thrombocytosis**, **hypokalemia**, and **hyperglycemia** is highly characteristic of Cushing syndrome due to chronic glucocorticoid excess.
- The patient's **truncal obesity** (BMI 37 kg/m2) and the metabolic derangements further support this diagnosis.
*Pheochromocytoma*
- While pheochromocytoma can cause **hypertension** and **tachycardia**, it typically presents with **episodic symptoms** like palpitations, sweating, and headaches.
- It does not explain the other prominent features such as **hirsutism**, **menstrual irregularities**, **proximal muscle weakness**, or **easy bruising**.
*Primary hyperaldosteronism*
- This condition is characterized by **hypertension** and **hypokalemia**, often leading to fatigue.
- However, it does not account for the patient's **hirsutism**, **menstrual irregularities**, **obesity**, **easy bruising**, **muscle weakness**, **acne**, or **hyperglycemia**.
*Polycystic ovarian syndrome*
- PCOS causes **irregular menses**, **hirsutism**, **acne**, and **obesity**, which are present in this patient.
- However, it typically does not cause **hypertension**, **hypokalemia**, **easy bruising**, or **proximal muscle weakness**, making Cushing syndrome a more encompassing diagnosis.
*Hypothyroidism*
- Hypothyroidism can lead to **fatigue**, **menstrual irregularities**, and **weight gain**.
- However, it typically presents with **bradycardia**, **dry skin**, **constipation**, and **cold intolerance**, not **hypertension**, **hirsutism**, **acne**, **easy bruising**, or **proximal muscle weakness**.
Weight gain recommendations US Medical PG Question 8: A 42-year-old man presents with palpitations, 2 episodes of vomiting, and difficulty breathing for the past hour. He says he consumed multiple shots of vodka at a party 3 hours ago but denies any recent drug use. The patient denies any similar symptoms in the past. Past medical history is significant for type 2 diabetes mellitus diagnosed 2 months ago, managed with a single drug that has precipitated some hypoglycemic episodes, and hypothyroidism diagnosed 2 years ago, well-controlled medically. The patient is a software engineer by profession. He reports a 25-pack-year smoking history and currently smokes 1 pack a day. He drinks alcohol occasionally but denies any drug use. His blood pressure is 100/60 mm Hg, pulse is 110/min, and respiratory rate is 25/min. On physical examination, the patient appears flushed and diaphoretic. An ECG shows sinus tachycardia. Which of the following medications is this patient most likely taking to explain his symptoms?
- A. Pioglitazone
- B. Tolbutamide (Correct Answer)
- C. Levothyroxine
- D. Sitagliptin
- E. Metformin
Weight gain recommendations Explanation: ***Tolbutamide***
- **Tolbutamide** is a first-generation sulfonylurea, which can cause a **disulfiram-like reaction** when consumed with alcohol, though this is more classically associated with chlorpropamide.
- Symptoms like palpitations, flushing, vomiting, and dyspnea are consistent with a disulfiram-like reaction due to the accumulation of **acetaldehyde**.
- The history of **hypoglycemic episodes** supports the use of a sulfonylurea, as these drugs stimulate insulin release and commonly cause hypoglycemia.
*Pioglitazone*
- **Pioglitazone** is a thiazolidinedione that improves insulin sensitivity but is not known to interact with alcohol to cause acute, severe symptoms like those described.
- Its main side effects include **fluid retention**, weight gain, and an increased risk of heart failure, which are not present here.
- It rarely causes hypoglycemia as monotherapy.
*Levothyroxine*
- **Levothyroxine** is a synthetic thyroid hormone used for hypothyroidism and does not interact with alcohol to produce a disulfiram-like reaction.
- Overdosing could cause symptoms of **hyperthyroidism**, but this interaction with alcohol is highly specific to certain diabetes medications.
*Sitagliptin*
- **Sitagliptin** is a DPP-4 inhibitor that helps lower blood glucose but does not cause a disulfiram-like reaction with alcohol.
- Side effects typically include **nasopharyngitis** and headache, unrelated to the patient's acute presentation.
- It has a low risk of hypoglycemia as monotherapy.
*Metformin*
- **Metformin** is a biguanide that reduces hepatic glucose production and increases insulin sensitivity. While alcohol consumption with metformin can increase the risk of **lactic acidosis**, it does not typically cause the flushing, palpitations, and vomiting seen here.
- The patient's symptoms are more characteristic of acetaldehyde accumulation.
- Metformin rarely causes hypoglycemia as monotherapy.
Weight gain recommendations US Medical PG Question 9: A 29-year-old G1P0 presents to her obstetrician for her first prenatal care visit at 12 weeks gestation by last menstrual period. She states that her breasts are very tender and swollen, and her exercise endurance has declined. She otherwise feels well. She is concerned about preterm birth, as she heard that certain cervical procedures increase the risk. The patient has a gynecologic history of loop electrosurgical excision procedure (LEEP) for cervical dysplasia several years ago and has had negative Pap smears since then. She also has mild intermittent asthma that is well controlled with occasional use of her albuterol inhaler. At this visit, this patient’s temperature is 98.6°F (37.0°C), pulse is 69/min, blood pressure is 119/61 mmHg, and respirations are 13/min. Cardiopulmonary exam is unremarkable, and the uterine fundus is just palpable at the pelvic brim. Pelvic exam reveals normal female external genitalia, a closed and slightly soft cervix, a 12-week-size uterus, and no adnexal masses. Which of the following is the best method for evaluating for possible cervical incompetence in this patient?
- A. Transabdominal ultrasound in the first trimester
- B. Transvaginal ultrasound in the first trimester
- C. Serial transvaginal ultrasounds starting at 16 weeks gestation
- D. Transabdominal ultrasound at 18 weeks gestation
- E. Transvaginal ultrasound at 18 weeks gestation (Correct Answer)
Weight gain recommendations Explanation: ***Transvaginal ultrasound at 18 weeks gestation***
- A history of **LEEP** is a risk factor for **cervical incompetence** and warrants screening with transvaginal ultrasound.
- The optimal timing for **cervical length** screening in women with a history of cervical procedures is typically between **18 and 24 weeks gestation**, as the risk of cervical shortening usually manifests during this period.
*Transabdominal ultrasound in the first trimester*
- **Transabdominal ultrasound** is generally not ideal for precise **cervical length measurement** due to potential shadowing from the fetus or maternal obesity.
- **First-trimester cervical length measurement** is not typically recommended for routine screening of cervical incompetence, as changes are less pronounced early in pregnancy.
*Transvaginal ultrasound in the first trimester*
- While more accurate than transabdominal, **first-trimester transvaginal ultrasound** for cervical length is not standard for predicting cervical incompetence.
- Significant cervical shortening due to incompetence often occurs later in the second trimester, so early screening may miss the condition.
*Serial transvaginal ultrasounds starting at 16 weeks gestation*
- While **serial transvaginal ultrasounds** starting at 16 weeks can be part of a management plan for high-risk patients, the most critical single assessment typically occurs at **18-24 weeks**.
- Starting serial scans too early may not be necessary if the cervix is long and closed at the initial key screening, unless there are other strong indications.
*Transabdominal ultrasound at 18 weeks gestation*
- Similar to first-trimester transabdominal ultrasound, **transabdominal imaging** at 18 weeks is generally **less accurate** than transvaginal for measuring cervical length.
- **Transvaginal ultrasound** offers a clearer and more precise view of the cervix, which is crucial for assessing potential shortening or funneling.
Weight gain recommendations US Medical PG Question 10: A 26-year-old woman presents to the women’s health clinic with a 9-week delay in menses. The patient has a history of grand mal seizures, and was recently diagnosed with acute sinusitis. She is prescribed lamotrigine and amoxicillin. The patient smokes one-half pack of cigarettes every day for 10 years, and drinks socially a few weekends every month. Her mother died of breast cancer when she was 61 years old. The vital signs are stable during the current office visit. Physical examination is grossly normal. The physician orders a urine beta-hCG that comes back positive. Abdominal ultrasound shows an embryo consistent in dates with the first day of last menstrual period. Given the history of the patient, which of the following would most likely decrease congenital malformations in the newborn?
- A. Decrease alcohol consumption
- B. Switching to cephalexin
- C. Folic acid supplementation (Correct Answer)
- D. Smoking cessation
- E. Switching to another antiepileptic medication
Weight gain recommendations Explanation: ***Folic acid supplementation***
- **Folic acid** (vitamin B9) is crucial in early pregnancy for **neural tube development** and significantly reduces the risk of **neural tube defects** and other congenital malformations.
- Given the patient’s history of **lamotrigine** use, which can increase the risk of neural tube defects, folic acid supplementation is even more critical.
*Decrease alcohol consumption*
- While **alcohol cessation** is important to prevent **fetal alcohol syndrome** and other alcohol-related developmental issues, it primarily affects neurological development and facial dysmorphology rather than primarily preventing
- The effects of alcohol are typically more pronounced with **chronic heavy consumption**, and while any reduction is beneficial, it is not the most likely intervention to decrease general congenital malformations.
*Switching to cephalexin*
- **Amoxicillin** is considered **safe in pregnancy** and is a penicillin-class antibiotic, while **cephalexin** is a cephalosporin.
- Switching antibiotics from one safe drug to another without a clear medical indication (e.g., allergy, resistance) would **not decrease the risk of congenital malformations**.
*Smoking cessation*
- **Smoking cessation** is vital during pregnancy as it reduces the risk of **low birth weight**, **preterm birth**, and other complications like placental abruption.
- However, the primary link of smoking is not directly with **congenital malformations** like neural tube defects, but rather with growth restriction and adverse perinatal outcomes.
*Switching to another antiepileptic medication*
- This patient is on **lamotrigine**, which is considered one of the **safer antiepileptic drugs (AEDs)** in pregnancy, especially compared to others like **valproic acid**.
- Switching to an alternative AED might even carry a **higher risk for congenital malformations** and is generally not recommended unless lamotrigine is ineffective or contraindicated.
More Weight gain recommendations US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
